Selumetinib was combined with different PI3K/mTOR inhibitors, such as the PI3K inhibitor BEZ235 or the mTOR kinase blocker AZD8055, leading to in vitro synergistic reduction of cell viability, enhanced apoptosis (34,38), in vivo tumor regression and extension of median survival (58–60). The gene discussed is MTOR; the disease is neoplasm.